<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Postoperative parenteral nutrition in adults</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Postoperative parenteral nutrition in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Postoperative parenteral nutrition in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Nicole Siparsky, MD, FACS, FCCM</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Amalia Cochran, MD, FACS, FCCM</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kathryn A Collins, MD, PhD, FACS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 01, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2040546877"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Malnutrition is associated with postoperative complications and an increased risk for death after surgery [<a href="#rid1">1</a>]. Many surgical diseases result in malnutrition, particularly those that are associated with a hypermetabolic state. Advanced age is also associated with malnutrition in hospitalized patients, many of whom require emergency operations [<a href="#rid2">2</a>]. Although optimization of nutrition prior to surgery is an option for a select group of patients, this is not possible in most cases [<a href="#rid3">3</a>]. (See  <a class="medical medical_review" href="/z/d/html/2880.html" rel="external">"Overview of perioperative nutrition support", section on 'Preoperative nutrition support'</a>.)</p><p>Enteral nutrition support is preferred for all patients who do not have a contraindication. The insertion and maintenance of the enteral feeding tube is safer for the patient and less costly compared with central venous catheter insertion and maintenance for the administration of <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a>. Enteral nutrition also contributes to the health of the intestinal border over time, preventing secondary complications, while long-term parenteral nutrition causes steatohepatitis. By comparison, even though premanufactured parenteral nutrition is available, individualized parenteral nutrition must be prepared in a sterile environment using a recipe customized for the patient, refrigerated due to limited stability, and, when used in the home, must be transported directly to the patient and used within 24 to 48 hours after removal from refrigeration [<a href="#rid4">4</a>]. After the initiation of therapy, enteral nutrition recipients require less monitoring, whereas parenteral nutrition recipients require regular monitoring (eg, laboratory tests on a weekly and later monthly basis) [<a href="#rid5">5</a>]. In spite of these drawbacks, parenteral nutrition support is necessary for postoperative patients with contraindications to enteral nutrition and/or who are unable to meet their nutritional goals using the enteral route. </p><p>The indications and implementation of <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a> in the stable (ie, not critically ill) postoperative patient are reviewed. The consequences of malnutrition, nutritional assessment, indications for preoperative nutrition support, and implementation of enteral nutrition in surgical patients are reviewed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2880.html" rel="external">"Overview of perioperative nutrition support"</a> and  <a class="medical medical_review" href="/z/d/html/817.html" rel="external">"Clinical assessment and monitoring of nutrition support in adult surgical patients"</a>.)</p><p>Nutrition support in specific patient populations is also discussed in more detail in separate topic reviews:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1617.html" rel="external">"Nutrition support in intubated critically ill adult patients: Initial evaluation and prescription"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/821.html" rel="external">"Overview of nutrition support in burn patients"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2830.html" rel="external">"The role of parenteral and enteral/oral nutritional support in patients with cancer"</a>.)</p><p></p><p class="headingAnchor" id="H2806568197"><span class="h1">INDICATIONS</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">Parenteral nutrition</a> provides support for patients in whom enteral feeding is insufficient in meeting nutritional goals or is contraindicated. In postoperative general surgery patients, enteral nutrition cannot be used due to the following conditions:</p><p class="bulletIndent1"><span class="glyph">●</span>Gastrointestinal anastomotic failure may cause peritoneal soiling and peritonitis. Uncontrolled anastomotic leak leads to contamination of the peritoneal cavity and is a contraindication to enteral feeding.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Gastrointestinal fistulas can arise for a variety of reasons (eg, anastomotic leak, pancreatitis, inflammatory bowel disease) [<a href="#rid6">6</a>]. Enteral feeding can increase drainage through a fistula, which can delay fistula closure. Management of gastrointestinal fistula may include <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a> for those with a high-output fistula (eg &gt;500 mL/day), especially for those who become volume depleted, have electrolyte abnormalities, or develop malnutrition or lose weight in spite of appropriate enteral supplements and medical therapy to control the fistula [<a href="#rid7">7</a>]. (See  <a class="medical medical_review" href="/z/d/html/15157.html" rel="external">"Enterocutaneous and enteroatmospheric fistulas"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Postoperative mechanical bowel obstruction is associated with stasis of intestinal contents proximal to the obstruction, which results in bowel distension, nausea, vomiting, and pain. Postoperative ileus can similarly cause nausea, vomiting, and pain. While enteral nutrition is preferred during the interim period of conservative management of postoperative ileus or bowel obstruction, <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a> support may become necessary. (See  <a class="medical medical_review" href="/z/d/html/89300.html" rel="external">"Management of small bowel obstruction in adults"</a> and  <a class="medical medical_review" href="/z/d/html/8042.html" rel="external">"Postoperative ileus"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Postoperative delayed gastric emptying is commonly observed after gastric and pancreatic surgery. In some cases, when intubation of the small intestine is not possible, delayed gastric emptying precludes safe enteral nutrition in the early postoperative period [<a href="#rid8">8</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chyle leak is an uncommon complication of surgery for which supportive care that includes oral or enteral dietary modification is often effective treatment. For patients who do not respond, withholding an enteral diet and administering <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a> is an option [<a href="#rid9">9</a>]. (See  <a class="medical medical_review" href="/z/d/html/1235.html" rel="external">"Chylous, bloody, and pancreatic ascites"</a> and  <a class="medical medical_review" href="/z/d/html/16356.html" rel="external">"Management of chylothorax"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Supplemental <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a> should also be considered in surgical patients whose nutritional needs are not being met using an enteral route, such as in those with inadequate absorptive capacity (short bowel syndrome), malabsorption (eg, inflammatory bowel disease, radiation enteritis), or in those with underlying conditions associated with chronic gastrointestinal dysmotility (eg, chronic pseudo-obstruction) [<a href="#rid10">10-12</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Feeding tube complications can arise either early or late with feeding tube use (eg, gastrostomy, jejunostomy placement). When complications arise, enteral nutrition is often suspended to minimize further complications (eg, leaking into the abdomen) [<a href="#rid13">13</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pre-existing malnutrition contributes to postoperative complications, including prolonged hospital stay, poor wound healing at surgical sites, and postoperative infection (eg, pneumonia). In a study of underweight patients undergoing gastrointestinal surgery with short-term contraindications to early enteral nutrition, <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a> support prolonged hospital stay by less than a day without a significant impact on rates of hospital-acquired pneumonia, urinary tract infection, or 28-day in-hospital mortality [<a href="#rid14">14</a>]. Outcome benefits in other subset populations, including the trauma patient population, may be less impressive and are being studied. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients who began <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a> support preoperatively due to chronic malnutrition, parenteral nutrition support is continued until sufficient enteral nutrition can be given to meet the nutritional demands of the patient [<a href="#rid15">15,16</a>]. (See  <a class="medical medical_review" href="/z/d/html/2880.html" rel="external">"Overview of perioperative nutrition support", section on 'Preoperative nutrition support'</a>.)</p><p></p><p class="headingAnchor" id="H2846580356"><span class="h1">CONTRAINDICATIONS</span></p><p class="headingAnchor" id="H532537783"><span class="h2">Absolute</span><span class="headingEndMark"> — </span>Absolute contraindications to <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a> in the postoperative surgical patient include the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ability to receive enteral feeding</strong> – Patients who can eat or receive enteral nutritional therapy should not receive <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a>. For patients who can eat but are unable to meet their nutritional goals by eating, enteral nutrition can usually be administered through a temporary feeding tube, which can be inserted and maintained with less risk of complications compared with central venous access, which is necessary to administer parenteral nutrition. Enteral formulas are also less expensive and do not require refrigeration. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anticipated duration of fasting is less than five days </strong>– During a period of fasting, glycogen serves as fuel for the body for up to 24 hours [<a href="#rid17">17</a>]. Insulin secretion falls with fasting as well, which can lead to muscle breakdown for fuel [<a href="#rid18">18</a>]. Basal insulin secretion can be maintained with the administration of dextrose-containing fluid (eg, dextrose 5% or dextrose 10%), thereby initially preventing muscle breakdown, but eventually this effect is lost, and nutrition support must be implemented to avoid muscle breakdown. Healthy patients generally tolerate periods of fasting up to 14 days without a significant impact on their recovery. However, malnourished patients who are starved after surgery have higher morbidity and mortality. For these reasons, nutrition guidelines recommend delaying the initiation of <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a> for up to seven days in healthy patients but starting parenteral nutrition as early as possible in malnourished patients [<a href="#rid19">19</a>]. (See <a class="local">'Timing'</a> below.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Terminal illness with short life expectancy </strong>– <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">Parenteral nutrition</a> support is unlikely to prolong life or improve quality-of-life in terminally ill patients with a short life expectancy (variably defined, but certainly less than one month) [<a href="#rid20">20</a>]. Whether patients with intermediate-length life expectancy benefit from provision from parenteral nutrition is controversial [<a href="#rid21">21-23</a>]. </p><p></p><p class="bulletIndent1">On the other hand, for patients with a longer life expectancy (&gt;3 months), it is reasonable to conclude that <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a> will prolong their lives, but with added risk. As an example, in postsurgical patients with recurrence of gynecologic malignancy, malignant bowel obstruction is common. In most cases, curative surgery is not an option, but symptoms can be palliated with gastrointestinal decompression. In the absence of hydration, survival is measured in days. With parenteral nutrition support, longer survival is possible. In a historical cohort study of 55 patients with terminal intestinal obstruction due to ovarian cancer, parenteral nutrition was associated with a significantly longer median survival [<a href="#rid24">24</a>]. The median survival from time of diagnosis of intestinal obstruction for patients receiving parenteral nutrition (TPN) was 72 days (range of 16 to 485 days) compared with 41 days (range of 4 to 133 days) for those not receiving parenteral nutrition; however, the difference in survival was not significant when adjusted for chemotherapy. These benefits are not seen in other inflammatory cancers, and it is theorized that patients with noninflammatory cancers benefit from nutrition support, whereas those with cancers that cause systemic inflammation and catabolism may not. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Refusal of or advanced directive against artificial feeding</strong> – <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">Parenteral nutrition</a> is a medical therapy and should not be used for patients who have declared their wishes against artificial feeding in general, or parenteral nutrition specifically, in person, in an advanced directive, or via a surrogate.</p><p></p><p class="headingAnchor" id="H4179207230"><span class="h2">Relative</span><span class="headingEndMark"> — </span>Patients with appropriate nutritional indications for <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a> support may have a clinical course (eg, shock, sepsis) that mandates the delay of initiation, or discontinuation of established parenteral nutrition support. Other complicating conditions (eg, volume overload, severe electrolyte disturbance) may make the parenteral nutrition prescription difficult to formulate. The most important of these are discussed briefly below. When the complicating condition has been adequately controlled, parenteral nutrition support can be resumed.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Shock</strong> – Administration of <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a> in the setting of hemodynamic instability remains controversial. Parenteral nutrition can worsen the condition of a patient in shock. The optimal timing of when parenteral nutrition can be safely instituted as shock resolves remains unclear. (See  <a class="medical medical_review" href="/z/d/html/1617.html" rel="external">"Nutrition support in intubated critically ill adult patients: Initial evaluation and prescription"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Catheter-related infection</strong> – For patients with bacteremia/fungemia, withholding nutrition support may be necessary if an intervening "line-free" period is needed to clear the infection. It is common for providers to withhold <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a> until there is evidence of resolution of bacteremia/fungemia (eg, negative subsequent blood cultures). In a meta-analysis, parenteral nutrition was a major risk factor for catheter-associated invasive candida infection in critically ill patients [<a href="#rid25">25</a>]. (See  <a class="medical medical_review" href="/z/d/html/3814.html" rel="external">"Intravascular non-hemodialysis catheter-related infection: Treatment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acid-base disturbance</strong> – Acid-base disturbances are common in the postoperative patient, resulting from large-volume gastrointestinal fluid loss, bleeding, under-resuscitation, and resuscitation with certain intravenous fluids. These include lactic acidosis and contraction alkalosis. Caution is advised in administering <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a> prior to completion of resuscitation, as parenteral nutrition can contribute to lactic acidosis in a stressed surgical patient [<a href="#rid26">26</a>]. Similarly, parenteral nutrition can complicate the interpretation of contraction alkalosis through the delivery of acetate, which is converted to bicarbonate and contributes to alkalosis. (See  <a class="medical medical_review" href="/z/d/html/106524.html" rel="external">"Overview of postoperative electrolyte abnormalities", section on 'Acid-base imbalance'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Severe electrolyte disturbance</strong> – In the setting of abnormalities in potassium, phosphate, and magnesium levels, aggressive electrolyte monitoring and correction is warranted to avoid complications. Caution is advised in prescribing <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a> electrolytes in cases of severe electrolyte disturbance and/or renal dysfunction. As an example, in cases of hyperkalemia associated with acute renal failure, the administration of potassium-containing parenteral nutrition can lead to arrhythmia. (See  <a class="medical medical_review" href="/z/d/html/106524.html" rel="external">"Overview of postoperative electrolyte abnormalities", section on 'Etiologies of postoperative electrolyte abnormalities'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Refeeding syndrome</strong> – In the setting of chronic malnutrition, especially with chronic electrolyte losses, the administration of <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a> can result in refeeding syndrome. With the initiation of parenteral nutrition, brisk decrements in serum electrolyte levels are often observed, resulting in hypokalemia, hypophosphatemia, and/or hypomagnesemia. To avoid complications of refeeding syndrome, electrolytes should be monitored closely for the first few days of parenteral nutrition administration, even as often as several times daily when there are severely low levels or sudden drops in levels. Electrolyte deficits should be aggressively corrected by intravenous replacement to prevent complications. Similarly, it may be appropriate to reduce the caloric content for the first few days of parenteral nutrition administration, or to stop the parenteral nutrition until severe deficiencies are corrected. Any patient with chronic starvation should be screened for <a class="drug drug_general" data-topicid="9988" href="/z/d/drug information/9988.html" rel="external">thiamine</a> deficiency (eg, thiamine) or receive a prophylactic dose of thiamine [<a href="#rid27">27</a>]. (See  <a class="medical medical_review" href="/z/d/html/106524.html" rel="external">"Overview of postoperative electrolyte abnormalities", section on 'Refeeding syndrome'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Volume overload</strong> – <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">Parenteral nutrition</a> is typically prepared in a predesignated volume of fluid required by the patient. However, the concentration of parenteral nutrition is limited by the concentrations of its component base macronutrients (eg, dextrose, amino acids, and intravenous lipid emulsion). Minerals (eg, calcium, phosphorus), which will precipitate if overconcentrated, may also determine minimum parenteral nutrition volumes. In patients with clinical features of volume overload (eg, respiratory insufficiency secondary to pulmonary edema), the risk of further overload must be considered prior to administering parenteral nutrition. (See <a class="local">'Complications'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lack of central venous access</strong> – Since <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a> support requires venous access for delivery, lack of appropriate access prevents administration. While parenteral nutrition can be given into a peripheral vein, large volumes are required, and higher concentrations tend to cause phlebitis, often necessitating a central access route. Parenteral nutrition that is not delivered into a central vein should only be used for brief periods of time, to prevent possible complications. (See  <a class="medical medical_review" href="/z/d/html/115957.html" rel="external">"Central venous access: Device and site selection in adults", section on 'Nature of infusate'</a> and  <a class="medical medical_review" href="/z/d/html/2797.html" rel="external">"Extravasation injury from cytotoxic and other noncytotoxic vesicants in adults"</a>.) </p><p></p><p class="headingAnchor" id="H3863139972"><span class="h1">TIMING</span></p><p class="headingAnchor" id="H887604355"><span class="h2">Initiation</span><span class="headingEndMark"> — </span>For those with appropriate indications, the timing of initiation of <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a> is largely based on the patient's clinical condition and preoperative nutritional status. Randomized trials comparing early initiation of parenteral nutrition to later initiation in critically ill patients suggest overall harm from early initiation [<a href="#rid28">28</a>]. (See  <a class="medical medical_review" href="/z/d/html/1626.html" rel="external">"Nutrition support in intubated critically ill adult patients: Parenteral nutrition"</a>.)</p><p>For most non-critically ill patients, the risks associated with postoperative <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a> usually outweigh the benefit during the first five days of fasting. Recommendations for non-critically ill patients are based on direct evidence from small randomized trials, observational studies, and indirect evidence from larger trials in critically ill patients. From retrospective reviews, authors have concluded that patients who do not suffer from chronic malnutrition tolerate brief periods of fasting [<a href="#rid29">29</a>]. Patients who were well nourished prior to surgery often tolerate a period of starvation up to 14 days [<a href="#rid30">30</a>]. In the absence of a severe stress response (eg, shock, systemic inflammatory response syndrome [SIRS]), glycogen stores provide calories during the first 24 hours of fasting. Thereafter, providing dextrose-containing intravenous fluids postoperatively stimulates basal insulin secretion and minimizes proteolysis during fasting [<a href="#rid18">18,31</a>]. Approximately 400 to 500 kcal/day are needed for a 70 kg patient. Randomized trials comparing parenteral nutrition to prolonged starvation (&gt;14 days) among non-critically ill surgical patients have not been done, but in observational studies, prolonged starvation has been associated with higher complication rates compared with administration of parenteral nutrition. Thus, among patients who cannot receive enteral nutrition, the general consensus as expressed in published guidelines is as follows [<a href="#rid19">19,31</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>The institution of <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a> in non-critically ill patients should be delayed until at least five days after surgery in the absence of preoperative malnutrition.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>After 14 days of postoperative starvation in otherwise healthy patients, <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a> should be initiated. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with chronic malnutrition and anticipated prolonged bowel rest, it may be appropriate to institute <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a> earlier than five to seven days. In this subset of surgical patients, parenteral nutrition has been associated with lower complication rates and lower mortality compared with fasting.</p><p></p><p>Early studies expected <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a> support to improve outcomes in surgical patients but were disappointing [<a href="#rid32">32-35</a>]. Lactic acidosis was observed, and no mortality benefit was demonstrated, likely related to the stress response of surgery [<a href="#rid26">26,36</a>]. When enteral feeding is not feasible, early initiation of parenteral nutrition has <strong>not</strong> been associated with benefit and may increase complications. Most studies addressing the timing of parenteral nutrition have been performed in critically ill patients. In particular, a large randomized trial supported later, rather than earlier, initiation of parenteral nutrition in these patients [<a href="#rid28">28</a>]. Furthermore, in reviews of parenteral nutrition for critically ill patients without malnutrition, a short course of parenteral nutrition in the early postoperative period (&lt;5 days) compared with no nutrition failed to show an outcome difference and suggested increased morbidity [<a href="#rid28">28,37</a>]. A systematic review identified 27 trials evaluating nutrition support in patients undergoing elective general surgery procedures and found no significant differences in mortality or major complications for parenteral nutrition compared with standard care (usual oral diet plus <a class="drug drug_general" data-topicid="8711" href="/z/d/drug information/8711.html" rel="external">intravenous dextrose</a>) [<a href="#rid38">38</a>]. Major complications included pneumonia, intra-abdominal abscess, sepsis, catheter-related infection, myocardial infarction, pulmonary embolism, heart failure, stroke, renal failure, liver failure, and anastomotic leak. There were also no differences for parenteral nutrition initiated preoperatively compared with postoperatively. However, for malnourished patients, parenteral nutrition (overall) was associated with a significant reduction in complications (relative risk 0.52, 95% CI 0.30-0.91) but no mortality differences. Among trials focused on the postoperative period, parenteral nutrition was instituted between 4 and 18 days postoperatively [<a href="#rid32">32,33,35,39-51</a>]. </p><p class="headingAnchor" id="H3734479355"><span class="h2">Cessation</span><span class="headingEndMark"> — </span>The duration of <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a> is typically dictated by the patient's ability to receive oral or enteral nutrition. For some patients, it may be obvious that prolonged parenteral nutrition support will be necessary or, rarely, permanent (eg, short gut syndrome) [<a href="#rid52">52</a>]. </p><p>For patients in transition from parenteral to enteral therapy, the timing of discontinuation of parenteral therapy is variable. Once a patient's oral/enteral intake meets a significant portion of their daily fluid and caloric needs, parenteral therapy may be decreased or stopped. Many recovering patients require a transition period, during which parenteral therapy is weaned down as oral/enteral intake increases. In such cases, it is common to discontinue parenteral therapy when fluid goals are met and caloric goals exceed 60 percent of the patient's daily requirement. For patients with intestinal failure, bowel rehabilitation and protracted weaning may be needed. (See  <a class="medical medical_review" href="/z/d/html/15073.html" rel="external">"Overview of postoperative fluid therapy in adults", section on 'Monitoring and adjustments'</a> and <a class="local">'Transition to enteral and oral feeding'</a> below.)</p><p>The practice of weaning <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a> over hours to prevent acute hypoglycemia is rarely necessary and stems from experiences during the early period of parenteral nutrition when patients were overfed. In addition, it depends on the formula the patient receives; some contain insulin, which may affect serum glucose levels around the time of discontinuation. If there is concern for hypoglycemia, reducing the rate over a few hours is a common practice. Alternatively, point-of-care glucose assessments might be a means of ensuring safety and alleviating the need for tapering rates.</p><p class="headingAnchor" id="H1457994239"><span class="h1">ESTIMATING NUTRITIONAL REQUIREMENTS</span><span class="headingEndMark"> — </span>The goal of <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a> support is to meet the nutritional requirements of the postoperative surgical patient. Underfeeding and overfeeding should both be avoided, as each is associated with complications (eg, hyperglycemia, hepatic steatosis, poor wound healing, infection, inability to wean from ventilator) [<a href="#rid53">53</a>].</p><p>The caloric needs of the postoperative patient have largely been determined by estimating the degree of the patient's surgical stress. Major surgical interventions (entry into a major body cavity [cranium, chest, abdomen], joint surgery, spine surgery), trauma (eg, long-bone fracture, traumatic brain injury), or burn injury induce a metabolic response and catabolic state [<a href="#rid18">18,54-56</a>]. For patients with sepsis, pancreatitis, systemic inflammatory response syndrome [SIRS], acute respiratory distress syndrome [ARDS], massive transfusion requirement, or large surface area burns, the catabolic response may be more profound. The more profound the catabolism, the more severe the muscle wasting that can occur [<a href="#rid57">57,58</a>]. Patients with large surface area burn wounds are the most highly stressed, catabolic patients [<a href="#rid59">59</a>]. An extensive, separate literature guides therapy for this patient population, whose needs exceed those of most other surgery patients. (See  <a class="medical medical_review" href="/z/d/html/15073.html" rel="external">"Overview of postoperative fluid therapy in adults", section on 'Physiologic stress response to surgery'</a> and  <a class="medical medical_review" href="/z/d/html/818.html" rel="external">"Hypermetabolic response to moderate-to-severe burn injury and management"</a> and  <a class="medical medical_review" href="/z/d/html/821.html" rel="external">"Overview of nutrition support in burn patients"</a>.)</p><p>There is no universally accepted way to determine the difference between a mildly and more heavily stressed patient. Interventions, such as better control of pain, temperature, anxiety, and optimizing ventilation, can lower measured calorie consumption in severely stressed surgical, trauma, and burn patients. Indirect calorimetry remains the most accurate way to estimate the patient's calorie consumption, but it is cumbersome and not widely available. Matching calorie prescription to calorie delivery has not proven to be ideal for postoperative patients. Proxy markers of stress, including markers of a systemic inflammatory response (tachycardia, tachypnea, fever, leukocytosis, or leukopenia), are often used together with clinical judgment to determine the severity of stress. Mathematical formulas have been proposed to estimate the nutritional requirements of the postoperative patient, but there is no single universally accepted formula to estimate the patient's requirements. The American Society for Parenteral and Enteral Nutrition (ASPEN) has recommended the use of a simple weight-based (ideal body weight) estimate of 25 kcal/kg/day when indirect calorimetry is not available [<a href="#rid19">19</a>]. (See  <a class="medical medical_review" href="/z/d/html/820.html" rel="external">"Nutritional demands and enteral formulas for adult surgical patients", section on 'Calculating energy requirements'</a>.)</p><p>For the average surgery patient without large wounds or other catabolic states, 25 kcal/kg/day is a good starting point. For patients with catabolic states (eg, sepsis, head injury) or large wounds, we increase the estimate to 30 to 35 kcal/kg/day.</p><p>The initial caloric estimate is just a starting point for <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a> prescription. Adjustment to the daily calorie goal is based on many factors, including wound healing, weight gain, and ventilator weaning. Historically, serum protein production (eg, albumin, prealbumin, transferring, and C-reactive protein) was considered to be a marker of adequate nutrition, but this practice has been abandoned as our understanding that there is a lack of relationship between intake and the levels of these proteins has increased [<a href="#rid60">60,61</a>]. A more global assessment, including examination (eg, wound healing), functional status, and nitrogen balance, is used to judge the adequacy of nutrition in the postoperative patient. (See  <a class="medical medical_review" href="/z/d/html/817.html" rel="external">"Clinical assessment and monitoring of nutrition support in adult surgical patients", section on 'Monitoring nutrition support'</a>.)</p><p>Collection of urine for 24-hour measurement of nitrogen excretion has long been used to drive protein prescriptions. However, the collection depends on good renal function, which may be compromised in the postoperative patient. It remains an imperfect estimate [<a href="#rid62">62</a>].</p><p class="headingAnchor" id="H1412199668"><span class="h1">PRESCRIPTION</span><span class="headingEndMark"> — </span>The process of ordering, reviewing, compounding, labeling, and administration of <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a> is complex and prone to error. Institutional practices and policy should be based on published safe practices guidelines [<a href="#rid63">63-67</a>]. </p><p><a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">Parenteral nutrition</a> is ordered for 24-hour periods, often with a 12-hour lead time based on laboratory studies from hours prior; it should be viewed as a two-day process. Fluids and electrolytes are best managed with conservative prescriptions that anticipate what the patient will need once stabilized, with external supplementation (eg, intravenous doses) of electrolytes or fluid, as needed. In this way, overdosing is avoided, and supplementation occurs in a timely manner. </p><p class="headingAnchor" id="H1353691142"><span class="h2">Initial prescription</span><span class="headingEndMark"> — </span>The initial prescription of <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a> requires the following basic elements: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fluid volume</strong> – The initial volume of fluid should meet the anticipated fluid goals of the patient for 24 hours. For the average postoperative patient who is not expected to have significant ongoing fluid losses, 30 to 40 mL/kg/day is adequate. The exact minimum volume needed to prevent ingredient precipitation depends upon the content of the recipe. For the typical prescription in the average 70 kg adult, the minimum volume is typically approximately 1.5 to 1.75 liters. For patients in whom volume restriction is important, the minimum volume can be confirmed with the pharmacy. Similarly, for patients with high fluid losses (eg, enterocutaneous fistula, large open wound), a fluid prescription of up to 5 L/day is not unusual. (See  <a class="medical medical_review" href="/z/d/html/15073.html" rel="external">"Overview of postoperative fluid therapy in adults", section on 'Maintenance fluid therapy'</a>.)</p><p></p><p class="bulletIndent1">For patients with unpredictable fluid losses, supplemental intravenous fluid can be administered to meet daily fluid goals and titrated for ongoing fluid losses. Typically, the fluid chosen to supplement <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a> is based on the bodily fluid that is lost. As an example, large-volume gastric fluid loss (eg, bowel obstruction) is high in chloride; as such, 0.9% <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> may be chosen as a replacement fluid. (See  <a class="medical medical_review" href="/z/d/html/15073.html" rel="external">"Overview of postoperative fluid therapy in adults", section on 'Fluid resuscitation'</a> and  <a class="medical medical_review" href="/z/d/html/106524.html" rel="external">"Overview of postoperative electrolyte abnormalities"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Protein</strong> – Approximately 20 to 25 percent of the daily caloric needs of the average surgical patient is provided as protein. Based on consensus opinion, the average surgical patient should receive 1.2 to 2 g/kg/day of protein. Each gram of protein contains 4 kcal of energy and is delivered in <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a> by incorporating an amino acid solution. It is suggested that surgical patients with large wounds receive an additional 0.5 to 1 g/kg/day of protein. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lipids</strong> – Typically, 10 to 30 percent of the daily caloric requirement is met with lipid emulsion. Each gram of lipid contains 9 kcal of energy. For patients receiving lipid-based medications, such as <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">propofol</a> sedation, the lipid content contributed by the medication should be considered. In some institutions, lipids are administered as a separate infusion from the daily <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a> prescription. Consensus guidelines favor admixture of intravenous lipid emulsion (ie, soybean oil-containing intralipid) with the parenteral nutrition, the so-called total nutrient admixture (TNA) or 3-in-1 parenteral nutrition [<a href="#rid67">67</a>]. However, randomized trials are lacking. In our practice, we do not administer lipids in the setting of hypertriglyceridemia exceeding 350 mg/dL, since lipoprotein lipase is saturated [<a href="#rid68">68</a>]. However, if the triglyceride level is drawn during infusion of lipid (eg, parenteral nutrition administration, propofol administration), levels up to 400 mg/dL are widely accepted. If the triglyceride level is drawn off lipid infusion, a lower threshold of 250 mg/dL is often used in holding lipid treatment.</p><p></p><p class="bulletIndent1">For patients requiring <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a> for two weeks or less, a <a class="drug drug_general" data-topicid="8437" href="/z/d/drug information/8437.html" rel="external">plant oil-based lipid emulsion</a> (eg, Intralipid, Clinolipid, Nutrilipid) typically suffices. The authors use Intralipid 20% emulsion, which contains 20% soybean oil and 1.2% egg yolk phospholipid. (See <a class="local">'Short-term parenteral nutrition administration'</a> below.)</p><p></p><p class="bulletIndent1">Recipients of long-term <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a> support are at risk for cholestatic liver injury and parenteral nutrition-associated liver disease, which is commonly attributed to derangements in serum levels of alpha-tocopherol, phytosterol, and omega-6 polyunsaturated fatty acid [<a href="#rid69">69</a>]. To limit adverse effects in patients who require parenteral nutrition for more than two weeks, the authors substitute the <a class="drug drug_general" data-topicid="8437" href="/z/d/drug information/8437.html" rel="external">plant oil-based lipid emulsion</a> with an alternative (ie, SMOFlipid), which is felt to confer immunological, anti-inflammatory, and pro-regenerative benefits to the recipient at risk for parenteral nutrition-associated liver disease [<a href="#rid70">70</a>]. SMOFlipid contains soybean oil (30%), <a class="drug drug_general" data-topicid="10132" href="/z/d/drug information/10132.html" rel="external">medium chain triglycerides</a> (30%), olive oil (25%), and fish oil (15%) [<a href="#rid71">71</a>]. (See <a class="local">'Long-term parenteral nutrition administration'</a> below.)</p><p></p><p class="bulletIndent1">A subset of postoperative patients (critically ill with multiorgan dysfunction) may benefit from the immunomodulatory properties of fish oil-enriched <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a> (ie, SMOFlipid). However, few high-quality data exist to support this. In a noninferiority study, investigators demonstrated noninferiority of SMOFlipid compared with traditional olive oil-based formula (ie, Clinoleic) [<a href="#rid72">72</a>]. In a small, randomized study of fish oil-containing lipid emulsion (ie, Lipidem), nonsurgical patients with severe pancreatitis experienced improved outcomes and a decreased inflammatory response [<a href="#rid73">73</a>]. Many patients with necrotizing pancreatitis will go on to require surgical interventions; this remains an active focus of study. (See <a class="local">'Dyslipidemia'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Carbohydrates</strong> – Carbohydrate content (in the form of dextrose) typically makes up 50 to 60 percent of the patient's daily calories. Each gram of dextrose contains 3.4 kcal of energy. Carbohydrate content is adjusted based on the protein and lipid content to maintain the calorie goal with adjustments in protein or lipid additives: </p><p></p><div class="formulaContainer"><div class="formula"><p class="bulletIndent2">Carbohydrate daily calories = Total daily calories - Protein calories - Lipid calories</p></div></div><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Electrolytes and acid-base balance </strong>– Avoiding hypokalemia/hypophosphatemia/hypomagnesemia is important in optimizing return of bowel function and avoiding complications of electrolyte deficiency (eg, arrhythmia, seizure, weakness). Daily electrolyte monitoring is essential in tailoring a prescription to meet the postoperative patient's needs. Each day, electrolyte content can be added, subtracted, or adjusted to meet the patient's ongoing needs. (See <a class="local">'Prescription'</a> above and  <a class="medical medical_review" href="/z/d/html/106524.html" rel="external">"Overview of postoperative electrolyte abnormalities", section on 'Laboratory monitoring'</a>.) </p><p></p><p class="bulletIndent1">Daily electrolyte requirements for <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a> are as follows:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Sodium 1 to 2 mEq/kg/day (in the form of sodium chloride or <a class="drug drug_general" data-topicid="9926" href="/z/d/drug information/9926.html" rel="external">sodium acetate</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Chloride and acetate are adjusted for acid-base balance.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Potassium 1 to 2 mEq/kg/day (in the form of <a class="drug drug_general" data-topicid="9795" href="/z/d/drug information/9795.html" rel="external">potassium chloride</a>, <a class="drug drug_general" data-topicid="9792" href="/z/d/drug information/9792.html" rel="external">potassium acetate</a>, or <a class="drug drug_general" data-topicid="9799" href="/z/d/drug information/9799.html" rel="external">potassium phosphate</a>). It is highly recommended that only one form of potassium be used on any given day, when possible, to avoid mathematical errors in potassium dosage. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Magnesium 8 to 20 mEq/day (in the form of <a class="drug drug_general" data-topicid="9585" href="/z/d/drug information/9585.html" rel="external">magnesium sulfate</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Calcium 10 to 15 mEq/day (in the form of <a class="drug drug_general" data-topicid="9190" href="/z/d/drug information/9190.html" rel="external">calcium gluconate</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Phosphorus 20 to 40 mmol/day (in form of <a class="drug drug_general" data-topicid="10269" href="/z/d/drug information/10269.html" rel="external">sodium phosphate</a> or <a class="drug drug_general" data-topicid="9799" href="/z/d/drug information/9799.html" rel="external">potassium phosphate</a>).</p><p></p><p class="bulletIndent1">When choosing a potassium or sodium additive, the acid-base balance and chloride level should be considered. Acetate is added to <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a> as a buffer and to achieve acid-base balance as an alternative to chloride in patients with hyperchloremia. Acetate is converted to bicarbonate, which is helpful for patients with ongoing bicarbonate loss. For patients without this issue, acetate content is minimized. As an example, a patient with a pancreatic fistula (rich in bicarbonate) would benefit from <a class="drug drug_general" data-topicid="9792" href="/z/d/drug information/9792.html" rel="external">potassium acetate</a> rather than <a class="drug drug_general" data-topicid="9795" href="/z/d/drug information/9795.html" rel="external">potassium chloride</a> to replete bicarbonate. Conversely, a patient with hyperkalemia and renal failure will achieve acid-base balance with dialysis; thus, potassium and acetate content should be minimized in such a patient.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vitamins and trace elements</strong> – For most patients, vitamins and trace elements are provided as the intravenous equivalent of a multivitamin. Supplementary amounts can be added to treat specific deficiencies that may be present.</p><p></p><p class="headingAnchor" id="H612406508"><span class="h2">Ongoing monitoring and adjustments</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">Parenteral nutrition</a> can be prescribed on a daily or weekly basis in hospitalized patients, or on a monthly, quarterly, or even annual basis for those requiring chronic nutrition support. </p><p>Most postoperative patients require laboratory monitoring in the perioperative period [<a href="#rid67">67</a>]. Early in the course of <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a> support, it is common to check a daily chemistry panel. This is useful for identifying and treating electrolyte abnormalities, monitoring for refeeding syndrome, hyperglycemia, and hydration status. In the early postoperative period, it is common to add potassium, magnesium, and acetate until a stable recipe is achieved, as evidenced by normal blood chemistry.</p><p>As the fluid and electrolyte needs of the patient stabilize over days, <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a> recipes can be prescribed by the week. There is no standard time course for daily, weekly, and monthly ordering of parenteral nutrition, as it typically requires individual customization. Early on, weekly assessments will include triglyceride levels and liver function studies to monitor further for complications such as hyperlipidemia and steatohepatitis. Chronic parenteral nutrition recipients may have their prescriptions extended beyond one week and may undergo less frequent laboratory monitoring. </p><p><a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">Parenteral nutrition</a> can also be administered in a cycled fashion. Typically, stable recipes can be converted from 24-hour infusions to 12-, 16-, or 20-hour infusions, allowing the patient some time to be disconnected from the infusion. However, in some cases, ongoing fluid losses do not permit extended periods of time off parenteral nutrition. In these cases, a continuous infusion of a large volume of parenteral nutrition may be used. Alternatively, a standard volume of parenteral nutrition can be supplemented with separate administration of intravenous fluid. </p><p>Lastly, for patients in the hospital, <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a> is often ordered daily, regardless of the chronicity of administration. Similarly, the preparation is compounded in a specialized pharmacy, which may be offsite. It is common to obtain parenteral nutrition from a private, outside pharmacy. In such cases, the deliveries are often batched daily for cost reasons. Parenteral nutrition has a short shelf life; on average, it should be administered within 30 hours at room temperature or nine days if refrigerated [<a href="#rid65">65</a>]. </p><p class="headingAnchor" id="H3156007042"><span class="h2">Other prescription adjustments</span><span class="headingEndMark"> — </span>The nutritional needs of a postoperative patient are largely defined by the underlying disease process, the procedure performed, and any complications that result from the disease or procedure. In creating a customized <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a> prescription for the postoperative patient, one should consider the individual needs of each patient, including the following:</p><p class="headingAnchor" id="H843744392"><span class="h3">Renal disease</span><span class="headingEndMark"> — </span>Protein adjustment for renal disease is controversial. For patients with chronic kidney disease, dietary protein restriction may slow the progression of their renal disease. Conversely, patients on peritoneal dialysis regularly lose protein from peritoneal fluid, and aggressive supplementation has been proposed. Consultation with a renal nutritionist and/or nephrologist is advised to determine protein prescription requirements for patients with significant renal dysfunction. (See  <a class="medical medical_review" href="/z/d/html/7178.html" rel="external">"Dietary recommendations for patients with nondialysis chronic kidney disease"</a>.)</p><p class="headingAnchor" id="H2804103930"><span class="h3">Liver disease</span><span class="headingEndMark"> — </span>Patients with liver disease may metabolize amino acids unpredictably, depending on their degree of liver function. With progressive liver failure, the patient's ability to metabolize amino acids will be increasingly compromised, resulting in hepatic encephalopathy [<a href="#rid74">74</a>]. The American Society for Parenteral and Enteral Nutrition (ASPEN) 2016 guidelines recommend using the patient's dry weight or usual weight, rather than an actual weight, to estimate protein requirements in patients with liver failure and cirrhosis. This recommendation is based on expert consensus and recognizes that complications of liver failure (ascites, edema) often make actual weight an unreliable measurement for estimating a patient's protein needs. ASPEN recommends against restricting protein in liver failure [<a href="#rid19">19</a>]. The optimal dosing of amino acids for patients with liver failure is unknown [<a href="#rid75">75</a>], and many institutions do not alter the protein additive for liver disease [<a href="#rid74">74</a>]. Protein restriction may rarely be used as a last resort for brief periods in patients with hepatic encephalopathy unresponsive to medical interventions, such as a patient with worsening acute liver failure awaiting liver transplantation who suffers from hepatic encephalopathy refractory to medical treatment. Similarly, ASPEN advises against using branched-chair amino acid formulas in patients with hepatic encephalopathy due to a lack of evidence of benefit.</p><p class="headingAnchor" id="H1150863409"><span class="h3">Hyperglycemia</span><span class="headingEndMark"> — </span>Hyperglycemia is common in hospital and ambulatory patients receiving <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a> [<a href="#rid76">76</a>]. No specific alteration in carbohydrate content is recommended for patients with diabetes. However, blood glucose monitoring should be performed in a scheduled fashion to ensure normoglycemia, especially early in the administration of parenteral nutrition [<a href="#rid77">77</a>]. Insulin can be added to the parenteral nutrition once a stable recipe and a stable insulin regimen are established. </p><p class="headingAnchor" id="H1017122811"><span class="h3">High-volume fluid loss</span><span class="headingEndMark"> — </span>Voluminous and difficult to predict fluid shifts can occur during and after major cavity surgery, large surface area debridement, small bowel obstruction, ascites production in liver failure, open abdomen with a closed system suction dressing, and enterocutaneous fistula. The volume of <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a> can be adjusted to accommodate large fluid losses. Typically, the starting parenteral nutrition volume is weight based (30 to 40 mL/kg/day). Additional fluid requirements are supplemented with intravenous fluids to meet the goal volume for 24 hours. The parenteral nutrition volume can also be adjusted, often in increments of 500 to 1000 mL on a daily basis, for convenience. Uncommonly, chronic daily fluid needs exceeding 4 to 5 L/day can be met with the administration of supplemental intravenous fluids. (See  <a class="medical medical_review" href="/z/d/html/15073.html" rel="external">"Overview of postoperative fluid therapy in adults", section on 'Fluid resuscitation'</a>.)</p><p class="headingAnchor" id="H3493116546"><span class="h3">Chyle leak</span><span class="headingEndMark"> — </span>The loss of lymphatic fluid, such as in traumatic or surgical disruption of lymphatic channels of the neck, chest, abdomen, or lymph node basins, can lead to the loss of fluid, protein, and lymphocytes. Nonoperative management includes a variety of enteral feeding modification approaches, from a zero-fat diet to nothing by mouth. <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">Parenteral nutrition</a> is prescribed to meet deficits of nutrition during this therapy [<a href="#rid9">9</a>]. (See  <a class="medical medical_review" href="/z/d/html/16356.html" rel="external">"Management of chylothorax"</a> and  <a class="medical medical_review" href="/z/d/html/1235.html" rel="external">"Chylous, bloody, and pancreatic ascites"</a>.)</p><p class="headingAnchor" id="H3252914854"><span class="h3">Large wounds</span><span class="headingEndMark"> — </span>Consensus recommendations suggest additional protein and other supplements (eg, <a class="drug drug_general" data-topicid="9776" href="/z/d/drug information/9776.html" rel="external">vitamin C</a>, zinc) to promote collagen production when healing large wounds, particularly those healing by secondary intention. While these are integral nutrients in healing, data supporting their supplementation in the absence of deficiency are lacking in the general surgery patient. Some studies of burn patients have demonstrated decrements in serum vitamin C early in the treatment course [<a href="#rid78">78</a>]. Whether to provide supplement to burn patients is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/821.html" rel="external">"Overview of nutrition support in burn patients"</a>.)</p><p class="headingAnchor" id="H2119867909"><span class="h3">Obesity</span><span class="headingEndMark"> — </span>Enteral, but not parenteral, nutritional goals for patients who are obese and critically ill (body mass index [BMI] ≥30 kg/m<sup>2</sup>) are detailed in the American Society for Parenteral and Enteral Nutrition (ASPEN) and Society of Critical Care Medicine (SCCM) 2016 nutrition guidelines [<a href="#rid19">19</a>]. This consensus statement recommends underfeeding patients who are obese (ie, providing 65 to 70 percent of target energy requirements) based on caloric estimates obtained by indirect calorimetry. When indirect calorimetry is not available, weight-based caloric estimates and protein requirements can be calculated as follows:</p><p class="bulletIndent2"><span class="glyph">•</span>BMI 30 to 40 kg/m<sup>2</sup> – 11 to 14 kcal/kg <strong>actual body weight</strong>/day; 2 g/kg/day of protein</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>BMI 40 to 50 kg/m<sup>2 </sup>– 11 to 14 kcal/kg <strong>actual body weight</strong>/day; 2.5 g/kg/day of protein</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>BMI &gt;50 kg/m<sup>2 </sup>– 22 to 25 kcal/kg <strong>ideal body weight</strong>/day; 2.5 g/kg/day protein</p><p></p><p class="headingAnchor" id="H660584609"><span class="h3">Hypermetabolic states</span><span class="headingEndMark"> — </span>Postoperative patients with hypermetabolic states (eg, burns, head injury, polytrauma, sepsis, malignancy, inflammation, gastrointestinal dysfunction, and burns have nutritional requirements that exceed the average postoperative goal of 25 kcal/kg/day [<a href="#rid79">79-82</a>]. As an example, critically ill burn patients receiving <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a> may be provided as much as 7 g/kg/day of carbohydrate alone, which can result in hyperglycemia. In some extreme cases, more-than-usual lipid content (eg, 30 percent lipid in burn patient) may be used. Similarly, burn patients may be provided a minimum of 1.5 to 2 g/kg/day of protein. It is important to recognize patients that fall into the extreme hypermetabolic state and to support them appropriately. For these patients, obtaining an accurate resting energy expenditure (eg, by metabolic cart) is essential in avoiding underfeeding and overfeeding. (See  <a class="medical medical_review" href="/z/d/html/818.html" rel="external">"Hypermetabolic response to moderate-to-severe burn injury and management"</a>.)</p><p>Similarly, patients with traumatic brain injury require more aggressive nutrition support. The Mifflin St. Jeor, Ireton-Jones, and Penn State equations are often used to estimate the caloric needs of traumatic brain injury patients, although the gold standard for measuring energy expenditure is indirect calorimetry. These patients also require higher protein content than the average postoperative patient (1.5 to 2 g/kg/day) [<a href="#rid54">54</a>]. (See  <a class="medical medical_review" href="/z/d/html/2585.html" rel="external">"Overview of dietary trace elements"</a> and  <a class="medical medical_review" href="/z/d/html/2880.html" rel="external">"Overview of perioperative nutrition support"</a> and  <a class="medical medical_review" href="/z/d/html/1617.html" rel="external">"Nutrition support in intubated critically ill adult patients: Initial evaluation and prescription"</a>.)</p><p class="headingAnchor" id="H2145838665"><span class="h3">Respiratory failure</span><span class="headingEndMark"> — </span>Caloric adjustments are often made in the support provided to patients with persistent respiratory failure. When indirect calorimetry is not available to guide the estimate of a calorie goal, it is easy to underfeed or overfeed a patient.<strong> </strong>In the case of overfeeding, excess calorie administration results in prolonged time to weaning from ventilator. For this reason, empiric adjustments may be made when a patient's respiratory failure persists without explanation. </p><p class="headingAnchor" id="H3430059587"><span class="h3">Dyslipidemia</span></p><p class="headingAnchor" id="H693268343"><span class="h4">Short-term parenteral nutrition administration</span><span class="headingEndMark"> — </span>Derangements in total cholesterol, lipoprotein, and triglyceride levels are commonly observed in the adult surgical population. The relationship between pre-existing dyslipidemia and parenteral nutrition-associated dyslipidemia remains poorly understood; it is complex, depending upon lipid dosing, lipid metabolism prior to <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a> administration, and clinical factors. Hypertriglyceridemia (triglyceride &gt;200 mg/dL) appears to be the most widely studied derangement and is attributed to overfeeding. Hypertriglyceridemia results when the parenteral nutrition infusion rate exceeds the capacity of lipoprotein lipase to clear triglyceride from the blood. Risk factors for hypertriglyceridemia due to parenteral nutrition identified in a small, retrospective study of non-critically ill patients included: pre-existing hypertriglyceridemia, increased BMI, and glucose dosing &gt;3.1 g/kg/day. In this study, omega-3 fatty acid supplementation resulted in a nonsignificant reduction of hypertriglyceridemia. In a multicenter, prospective study, 26.2 percent of patients receiving parenteral nutrition developed hypertriglyceridemia; the majority of these patients (91.2 percent) presented one or more risk factors, including renal failure, hyperglycemia, corticoid administration, pancreatitis, and sepsis [<a href="#rid83">83</a>]. The patients in this study received a mean lipid dose that was low (0.83 g/kg/day). These risk factors are commonly observed in critically ill surgical patients. Thus, we advise close lipid monitoring in surgical patients, especially those who are critically ill and/or who receive lipid-based medication (eg, <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">propofol</a>) [<a href="#rid84">84</a>].</p><p>Scant data are available to provide standardized recommendations regarding the incorporation of specific lipid products when <strong>starting</strong> <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a> [<a href="#rid63">63</a>]. Historically, soybean oil was the first commercially available lipid emulsion. In spite of its inflammatory properties, its persistent use may be due to its lower cost and higher amount of fatty acids (eg, linoleic acid, alpha-linolenic acid [<a href="#rid85">85,86</a>]). Most "starter" parenteral nutritional formulas contain soybean oil, which may drive dyslipidemia in the first few weeks of parenteral nutrition administration. (See <a class="local">'Initial prescription'</a> above.) </p><p class="bulletIndent1"><span class="glyph">●</span>In a study of eight patients receiving Intralipid 10% emulsion, all demonstrated elevated low-density lipoprotein, phospholipid, and cholesterol [<a href="#rid87">87</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a comparative study, metabolic complications were more likely to develop in older patients receiving <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a>, but hypertriglyceridemia was infrequently observed (1.2 percent) in patients age ≥65 [<a href="#rid88">88</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective review of 172 patients undergoing <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a> for medical and surgical reasons, hypertriglyceridemia was observed far less frequently in older patients age &gt;80 years compared with patients age &lt;80 years (7 versus 36 percent) [<a href="#rid2">2</a>]. </p><p></p><p>For patients who develop dyslipidemia within the first two weeks of <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a>, the authors use the management strategies listed below:</p><p class="bulletIndent1"><span class="glyph">●</span>Exclude lipid from <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a> in the first one to two weeks of therapy. In one retrospective review, the withdrawal of lipid emulsion in hospitalized patients with hypertriglyceridemia was associated with a significant reduction in triglyceride level, although later reintroduction correlated to an increase in triglyceride level [<a href="#rid89">89</a>]. Caution is advised in withholding lipid for greater than two weeks, which can contribute to essential fatty acid deficiency. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For a triglyceride level &gt;250 mg/dL measured from a blood sample obtained while the patient is off lipid infusion, we advise discontinuation of the lipid component of <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a>. We monitor triglyceride levels weekly until they return to normal and reimplement lipid therapy at a lower dose thereafter.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We tolerate a triglyceride level up to 400 mg/dL when measured from a blood sample that is drawn while lipid is infusing. If the level exceeds 400 mg/dL, we advise discontinuation of the lipid component of <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a>. We monitor triglyceride levels weekly until they return to normal, and reimplement lipid therapy at a lower dose thereafter.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Administer the lipid component of <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a> separately. Space doses as far apart as possible to optimize recovery time in between. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Minimize the lipid dose as much as possible.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fish oil and omega-3 fatty acid administration may reduce the triglyceride level through different mechanisms.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Switch to an alternative lipid formulation (eg, SMOFlipid) as with dyslipidemia associated with long-term <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a>. (See <a class="local">'Long-term parenteral nutrition administration'</a> below.)</p><p></p><p>Liver enzymes (aspartate transaminase, alanine transaminase, alkaline phosphatase, gamma-glutamyl transpeptidase) are obtained daily, and a lipid panel is obtained intermittently to detect clinically impactful hepatic inflammation after starting <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a>. Caution is advised in interpreting typical inflammatory markers (eg, C-reactive protein, erythrocyte sedimentation rate) in the first six to eight weeks after surgery, when they are commonly deranged due to the inflammatory response associated with surgery.</p><p class="headingAnchor" id="H1760636793"><span class="h4">Long-term parenteral nutrition administration</span><span class="headingEndMark"> — </span>The impact of dyslipidemia associated with long-term <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a> administration is better established. Longstanding liver inflammation may result in dyslipidemia. This relationship is well established and is tied to the composition of the lipid formulation; omega-6 fatty acid, phytosterol, and omega-6 polyunsaturated fatty acid have all been implicated [<a href="#rid85">85,86,90</a>]. Long-term parenteral nutrition recipients (ie, &gt;2 weeks) benefit from further evaluation of their systemic inflammatory status; 2016 ASPEN guidelines recommend monitoring C-reactive protein, erythrocyte sedimentation rate, lipid panel, and liver enzymes. </p><p>Alternative fat emulsions (eg, SMOFlipid), including those containing medium-chain triglycerides, olive oil, and fish oil, have proven to be beneficial in minimizing or preventing chronic inflammation. When compared with soybean oil, these alternative formulations contain less omega-6 fatty acid, less or no phytosterol, and may confer beneficial immunomodulatory effects due to omega-3 fatty acid, increased antioxidants, and a reduction in inflammatory mediators [<a href="#rid91">91</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>In a randomized trial of SMOFlipid 20% versus medium-chain/long-chain triglycerides 20%, recipients of SMOFlipid demonstrated lower triglyceride levels, which was attributed to a better balanced fatty acid complement [<a href="#rid92">92</a>]. Case reports exist of reversal of liver disease with fish oil-based lipid formulations.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a meta-analysis of six trials, an association was found between SMOFlipid and lower levels of hepatic enzymes, low-density lipoprotein, triglyceride, and C-reactive protein levels, suggesting decreased liver toxicity with SMOFlipid administration compared with traditional soybean emulsion [<a href="#rid93">93</a>].</p><p></p><p>For patients who develop dyslipidemia or signs of worsening systemic inflammation (ie, elevated liver enzymes) while on long-term <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a>, it is important to consider the patient's clinical context. Inflammatory markers and liver enzymes may worsen with conditions commonly observed in the surgical patients including sepsis, medication-induced hepatotoxicity, and the sequelae of traumatic liver injury. </p><p>The following management strategies are used to adjust the lipid emulsion in response to dyslipidemia:</p><p class="bulletIndent1"><span class="glyph">●</span>If traditional soybean-based emulsion is employed, switch to SMOFlipid with ongoing monitoring.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If dyslipidemia or worsening systemic inflammation occurs on SMOFlipid, consider decreasing the amount of lipid administered, administration of supplements that lower triglyceride levels (eg, fish oil), cycling lipid infusion (allowing 6 to 12 hours of lipid-free time for recovery), or providing lipid separately administered once or twice weekly.</p><p></p><p class="headingAnchor" id="H1430928176"><span class="h1">TRANSITION TO ENTERAL AND ORAL FEEDING</span><span class="headingEndMark"> — </span>There is no universally accepted method of weaning from <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a>. Weaning the volume or time spent on parenteral nutrition is usually done in a methodical fashion [<a href="#rid94">94,95</a>]. To be fully liberated from nutrition support, the patient should be able to maintain their weight, nutrition, and hydration on an oral diet. (See  <a class="medical medical_review" href="/z/d/html/817.html" rel="external">"Clinical assessment and monitoring of nutrition support in adult surgical patients", section on 'Monitoring nutrition support'</a>.)</p><p>For patients with a reversible illness that is resolving with treatment (eg, bowel obstruction, sepsis, pancreatitis), the patient will reach a point where they will tolerate enteral feeding. </p><p class="bulletIndent1"><span class="glyph">●</span>After a short course of <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a> (ie, two to four weeks), parenteral nutrition can be discontinued when &gt;60 percent of the caloric needs are met enterally, although this number varies widely in practice. It is generally accepted that a recovering patient will continue to progressively improve and increase their caloric intake. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients receiving <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a> for a prolonged period of time (ie, &gt;1 month), a slower course of weaning from parenteral nutrition is advised. Typically, the patient should meet at least 80 percent of daily nutrition goals through enteral intake to maintain body weight and hydration. </p><p></p><p>In some cases, enteroclysis can be used to help liberate the patient from <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a>. The principle behind this process is the collection and refeeding of enteral drainage from one part of the gastrointestinal track to another. As an example, a patient with both a high-output duodenal fistula and jejunal fistula can undergo collection of duodenal effluent, which can be fed into the jejunal fistula with a soft feeding tube. This process allows for physiologic enteral feeding, which is superior to parenteral nutrition. However, the technique is challenging for providers and patients alike. Despite this, some patients are successfully liberated from parenteral nutrition in this manner [<a href="#rid7">7</a>]. </p><p>In some cases, patients who undergo parenteral therapy in hopes that a fistula will close fail to achieve fistula closure. As an example, a patient with an enterocutaneous fistula may have persistent drainage after months of enteral rest and <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a>. Such a patient will require surgery to be liberated from parenteral nutrition. </p><p class="headingAnchor" id="H483431871"><span class="h2">Intestinal rehabilitation</span><span class="headingEndMark"> — </span>In cases of extensive bowel resection (eg, short gut syndrome) or fistulization, some patients may not be able to survive without <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a> due to intestinal dumping and malabsorption, which leads to dehydration, malnutrition, and a host of vitamin deficiencies. Many borderline patients require formal gut rehabilitation to be safely liberated from parenteral nutrition. Patients who lose &gt;75 percent of their small bowel are expected to require dietary modification and/or parenteral nutrition. In particular, ileal resections result in bile salt and B12 malabsorption, which will worsen steatorrhea and vitamin absorption. Additionally, loss of the colon and/or ileocecal valve may contribute to a patient's parenteral nutrition dependence. (See  <a class="medical medical_review" href="/z/d/html/5894.html" rel="external">"Management of short bowel syndrome in children", section on 'Protocol for feeding advancement'</a> and  <a class="medical medical_review" href="/z/d/html/4773.html" rel="external">"Management of short bowel syndrome in adults", section on 'Weaning parenteral nutrition'</a>.)</p><p>Intestinal rehabilitation programs have yielded some useful insights into the transition from parenteral to enteral feeding. As patients recover from their illness, enteral nutrition can be modified as follows: </p><p class="bulletIndent1"><span class="glyph">●</span>Continuous or frequent small feeds saturate intestinal absorptive channels; thus, gradual introduction is recommended.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Diets should favor complex carbohydrates over simple sugars to avoid the osmotic load that generates diarrhea.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Protein-rich diets (ie, 20 percent protein) are more physiologic and are better tolerated.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>High fat (ie, 30 to 40 percent fat) is recommended; fat is tolerated better than a highly osmotic carbohydrate load.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fiber supplementation enhances adaptation and water absorption and can be constipating, which is good for patients with malabsorption.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Oxalate restriction and avoidance of foods high in <a class="drug drug_general" data-topicid="9776" href="/z/d/drug information/9776.html" rel="external">vitamin C</a> may be needed for patients with ileal resection &gt;100 cm; oxalate is absorbed more readily in states of bile acid deficit, leading to kidney stones.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Vitamin/mineral deficiencies may persist, depending on fat and vitamin absorption.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antimotility medication therapy is often needed to manage symptoms of malabsorption.</p><p></p><p class="headingAnchor" id="H1475566922"><span class="h1">COMPLICATIONS</span><span class="headingEndMark"> — </span>Complications of <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a> are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/1626.html" rel="external">"Nutrition support in intubated critically ill adult patients: Parenteral nutrition", section on 'Complications'</a>.)</p><p class="headingAnchor" id="H2732725777"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/111340.html" rel="external">"Society guideline links: Nutrition support (parenteral and enteral nutrition) in adults"</a>.)</p><p class="headingAnchor" id="H181783161"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>An enteral route for nutrition is generally recommended, but <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a> may be necessary for postoperative patients who have a contraindication to enteral nutrition (eg, postoperative anastomotic failure, mechanical bowel obstruction). Supplemental parenteral nutrition should also be considered in surgical patients whose nutritional needs are chronically not being met using an enteral route. Patients with appropriate nutritional indications for parenteral nutrition support may have a clinical course that complicates initiation or mandates discontinuing established parenteral support (eg, shock, refeeding syndrome). (See <a class="local">'Indications'</a> above and <a class="local">'Contraindications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The optimal timing for initiation of <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a> in the postoperative period remains controversial. For those with appropriate indications, the timing of initiation is largely based on the patient's clinical condition, expected time to recovery, and preoperative nutritional status. (See <a class="local">'Timing'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For non-critically ill postoperative patients who are adequately nourished, we suggest <strong>not</strong> initiating <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a> prior to five days postoperatively (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). Most surgical patients will tolerate a short period of supported fasting, during which intravenous fluids are often sufficient. Prolonged starvation (&gt;14 days) has been associated with higher complication rates compared with administration of parenteral nutrition. Thus, there is a general consensus that after 14 days, parenteral nutrition should be started. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For non-critically ill postoperative patients who are malnourished at the time of surgery and who are not expected to meet enteral nutrition goals within five days, we suggest early initiation of <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a> (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). In this subset of surgical patients, parenteral nutrition has been associated with lower complication rates when compared with fasting. (See  <a class="medical medical_review" href="/z/d/html/15073.html" rel="external">"Overview of postoperative fluid therapy in adults", section on 'Maintenance fluid therapy'</a>.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Recommendations for critically ill patients are similar and are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1617.html" rel="external">"Nutrition support in intubated critically ill adult patients: Initial evaluation and prescription"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a> prescription is determined by estimating the caloric, protein, lipid, and fluid needs of the postoperative patient. For the average surgical patient, a good initial estimate of required calories is 25 kcal/kg/day. A higher number of calories may be necessary for those with large wounds or other hypermetabolic states. Initial protein, lipid, and carbohydrate needs are reviewed above. Adjustments are made to customize the formula to account for coexisting conditions and ongoing nutritional and fluid and electrolyte needs. (See <a class="local">'Initial prescription'</a> above and <a class="local">'Other prescription adjustments'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The transition from parenteral to enteral nutrition is commonly achieved when the patient recovers from surgery and/or complications of surgery. Some patients require prolonged <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a> support and bowel rehabilitation. Rarely, chronic parenteral nutrition is necessary for those with intestinal failure. (See <a class="local">'Cessation'</a> above and <a class="local">'Transition to enteral and oral feeding'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Mogensen KM, Robinson MK, Casey JD, et al. Nutritional Status and Mortality in the Critically Ill. Crit Care Med 2015; 43:2605.</a></li><li><a class="nounderline abstract_t">Reilly F, Burke JP, O'Hanlon C, McNamara DA. Comparative outcomes of total parenteral nutrition use in patients aged greater or less than 80 years of age. J Nutr Health Aging 2015; 19:329.</a></li><li><a class="nounderline abstract_t">Santa Mina D, Scheede-Bergdahl C, Gillis C, Carli F. Optimization of surgical outcomes with prehabilitation. Appl Physiol Nutr Metab 2015; 40:966.</a></li><li><a class="nounderline abstract_t">Sadique Z, Harrison DA, Bear DE, et al. Effectiveness and cost-effectiveness of early nutritional support via the parenteral versus the enteral route for critically ill adult patients. J Crit Care 2019; 52:237.</a></li><li><a class="nounderline abstract_t">Berlana D, Almendral MA, Abad MR, et al. Cost, Time, and Error Assessment During Preparation of Parenteral Nutrition: Multichamber Bags Versus Hospital-Compounded Bags. JPEN J Parenter Enteral Nutr 2019; 43:557.</a></li><li><a class="nounderline abstract_t">Gribovskaja-Rupp I, Melton GB. Enterocutaneous Fistula: Proven Strategies and Updates. Clin Colon Rectal Surg 2016; 29:130.</a></li><li><a class="nounderline abstract_t">Polk TM, Schwab CW. Metabolic and nutritional support of the enterocutaneous fistula patient: a three-phase approach. World J Surg 2012; 36:524.</a></li><li><a class="nounderline abstract_t">Worsh CE, Tatarian T, Singh A, et al. Total parenteral nutrition in patients following pancreaticoduodenectomy: lessons from 1184 patients. J Surg Res 2017; 218:156.</a></li><li><a class="nounderline abstract_t">Sriram K, Meguid RA, Meguid MM. Nutritional support in adults with chyle leaks. Nutrition 2016; 32:281.</a></li><li><a class="nounderline abstract_t">Billiauws L, Corcos O, Joly F. Dysmotility disorders: a nutritional approach. Curr Opin Clin Nutr Metab Care 2014; 17:483.</a></li><li><a class="nounderline abstract_t">Schwartz E. Perioperative Parenteral Nutrition in Adults With Inflammatory Bowel Disease: A Review of the Literature. Nutr Clin Pract 2016; 31:159.</a></li><li><a class="nounderline abstract_t">Pironi L, Arends J, Baxter J, et al. ESPEN endorsed recommendations. Definition and classification of intestinal failure in adults. Clin Nutr 2015; 34:171.</a></li><li><a class="nounderline abstract_t">Blakely AM, Ajmal S, Sargent RE, et al. Critical analysis of feeding jejunostomy following resection of upper gastrointestinal malignancies. World J Gastrointest Surg 2017; 9:53.</a></li><li><a class="nounderline abstract_t">Otaka S, Aso S, Matsui H, et al. Associations between early parenteral nutrition and in-hospital outcomes in underweight patients with gastrointestinal surgery. Clin Nutr ESPEN 2021; 43:464.</a></li><li><a class="nounderline abstract_t">Sim J, Hong J, Na EM, et al. Early supplemental parenteral nutrition is associated with reduced mortality in critically ill surgical patients with high nutritional risk. Clin Nutr 2021; 40:5678.</a></li><li><a class="nounderline abstract_t">Koemans WJ, Houwink A, van der Kaaij RT, et al. Perioperative Management of Gastric Cancer Patients Treated With (Sub)Total Gastrectomy, Cytoreductive Surgery, and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Lessons Learned. Ann Surg Oncol 2021; 28:4647.</a></li><li><a class="nounderline abstract_t">Cherkas A, Golota S. An intermittent exhaustion of the pool of glycogen in the human organism as a simple universal health promoting mechanism. Med Hypotheses 2014; 82:387.</a></li><li><a class="nounderline abstract_t">Soeters MR, Soeters PB, Schooneman MG, et al. Adaptive reciprocity of lipid and glucose metabolism in human short-term starvation. Am J Physiol Endocrinol Metab 2012; 303:E1397.</a></li><li><a class="nounderline abstract_t">Taylor BE, McClave SA, Martindale RG, et al. Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.). Crit Care Med 2016; 44:390.</a></li><li><a class="nounderline abstract_t">Cass-Garcia M, Hodul PJ, Almhanna K. Use of total parenteral nutrition (TPN) in terminally ill gastrointestinal (GI) cancer patients (pts) compared to other malignancies (OM): A single-institution experience. J Clin Oncol 2013; 309:309.</a></li><li><a class="nounderline abstract_t">van de Vathorst S. Artificial nutrition at the end of life: ethical issues. Best Pract Res Clin Gastroenterol 2014; 28:247.</a></li><li><a class="nounderline abstract_t">Plonk WM Jr, Arnold RM. Terminal care: the last weeks of life. J Palliat Med 2005; 8:1042.</a></li><li><a class="nounderline abstract_t">Lembeck ME, Pameijer CR, Westcott AM. The Role of Intravenous Fluids and Enteral or Parenteral Nutrition in Patients with Life-limiting Illness. Med Clin North Am 2016; 100:1131.</a></li><li><a class="nounderline abstract_t">Brard L, Weitzen S, Strubel-Lagan SL, et al. The effect of total parenteral nutrition on the survival of terminally ill ovarian cancer patients. Gynecol Oncol 2006; 103:176.</a></li><li><a class="nounderline abstract_t">Thomas-Rüddel DO, Schlattmann P, Pletz M, et al. Risk Factors for Invasive Candida Infection in Critically Ill Patients: A Systematic Review and Meta-analysis. Chest 2022; 161:345.</a></li><li><a class="nounderline abstract_t">Degoute CS, Ray MJ, Manchon M, et al. Intraoperative glucose infusion and blood lactate: endocrine and metabolic relationships during abdominal aortic surgery. Anesthesiology 1989; 71:355.</a></li><li><a class="nounderline abstract_t">Walmsley RS. Refeeding syndrome: screening, incidence, and treatment during parenteral nutrition. J Gastroenterol Hepatol 2013; 28 Suppl 4:113.</a></li><li><a class="nounderline abstract_t">Casaer MP, Mesotten D, Hermans G, et al. Early versus late parenteral nutrition in critically ill adults. N Engl J Med 2011; 365:506.</a></li><li><a class="nounderline abstract_t">Rosenthal MD, Vanzant EL, Martindale RG, Moore FA. Evolving paradigms in the nutritional support of critically ill surgical patients. Curr Probl Surg 2015; 52:147.</a></li><li><a class="nounderline abstract_t">Koretz RL, Lipman TO, Klein S, American Gastroenterological Association. AGA technical review on parenteral nutrition. Gastroenterology 2001; 121:970.</a></li><li><a class="nounderline abstract_t">Weimann A, Braga M, Carli F, et al. ESPEN guideline: Clinical nutrition in surgery. Clin Nutr 2017; 36:623.</a></li><li><a class="nounderline abstract_t">Sandström R, Drott C, Hyltander A, et al. The effect of postoperative intravenous feeding (TPN) on outcome following major surgery evaluated in a randomized study. Ann Surg 1993; 217:185.</a></li><li><a class="nounderline abstract_t">Brennan MF, Pisters PW, Posner M, et al. A prospective randomized trial of total parenteral nutrition after major pancreatic resection for malignancy. Ann Surg 1994; 220:436.</a></li><li><a class="nounderline abstract_t">Holter AR, Fischer JE. The effects of perioperative hyperalimentation on complications in patients with carcinoma and weight loss. J Surg Res 1977; 23:31.</a></li><li><a class="nounderline abstract_t">Woolfson AM, Smith JA. Elective nutritional support after major surgery: a prospective randomised trial. Clin Nutr 1989; 8:15.</a></li><li><a class="nounderline abstract_t">Royle G, Kettlewell M. Liver function and lactate metabolism in the ill surgical patient. Br J Surg 1978; 65:661.</a></li><li><a class="nounderline abstract_t">Doig GS, Simpson F, Sweetman EA, et al. Early parenteral nutrition in critically ill patients with short-term relative contraindications to early enteral nutrition: a randomized controlled trial. JAMA 2013; 309:2130.</a></li><li><a class="nounderline abstract_t">Heyland DK, Montalvo M, MacDonald S, et al. Total parenteral nutrition in the surgical patient: a meta-analysis. Can J Surg 2001; 44:102.</a></li><li><a class="nounderline abstract_t">Abel RM, Fischer JE, Buckley MJ, et al. Malnutrition in cardiac surgical patients. Results of a prospective, randomized evaluation of early postoperative parenteral nutrition. Arch Surg 1976; 111:45.</a></li><li><a class="nounderline abstract_t">Reilly J, Mehta R, Teperman L, et al. Nutritional support after liver transplantation: a randomized prospective study. JPEN J Parenter Enteral Nutr 1990; 14:386.</a></li><li><a class="nounderline abstract_t">Figueras J, Puig P, Rafecas A, et al. Postoperative hypocaloric parenteral nutrition. A study in patients without neoplasm. Acta Chir Scand 1988; 154:435.</a></li><li><a class="nounderline abstract_t">Hu SS, Fontaine F, Kelly B, Bradford DS. Nutritional depletion in staged spinal reconstructive surgery. The effect of total parenteral nutrition. Spine (Phila Pa 1976) 1998; 23:1401.</a></li><li><a class="nounderline abstract_t">Hwang TL, Mou SC, Chen MF. The importance of a source of sufficient protein in postoperative hypocaloric partial parenteral nutrition support. JPEN J Parenter Enteral Nutr 1993; 17:254.</a></li><li><a class="nounderline abstract_t">Garden OJ, Smith A, Harris NW, et al. The effect of isotonic amino acid infusions on serum proteins and muscle breakdown following surgery. Br J Surg 1983; 70:79.</a></li><li><a class="nounderline abstract_t">Hogbin BM, Smith AM, Craven AH. An evaluation of peripheral essential amino acid infusion following major surgery. JPEN J Parenter Enteral Nutr 1984; 8:511.</a></li><li><a class="nounderline abstract_t">Doglietto GB, Gallitelli L, Pacelli F, et al. Protein-sparing therapy after major abdominal surgery: lack of clinical effects. Protein-Sparing Therapy Study Group. Ann Surg 1996; 223:357.</a></li><li><a class="nounderline abstract_t">Jiménez Jiménez FJ, Leyba CO, Jiménez Jiménez LM, et al. Study of hypocaloric peripheral parenteral nutrition in postoperative patients (European project). Clin Nutr 1995; 14:88.</a></li><li><a class="nounderline abstract_t">Askanazi J, Hensle TW, Starker PM, et al. Effect of immediate postoperative nutritional support on length of hospitalization. Ann Surg 1986; 203:236.</a></li><li><a class="nounderline abstract_t">Yamada N, Koyama H, Hioki K, et al. Effect of postoperative total parenteral nutrition (TPN) as an adjunct to gastrectomy for advanced gastric carcinoma. Br J Surg 1983; 70:267.</a></li><li><a class="nounderline abstract_t">Gys T, Peeters R, Hubens A. The value of short-term peripheral parenteral nutrition after colorectal surgery: a comparative study with conventional postoperative intravenous fluid. Acta Chir Belg 1990; 90:234.</a></li><li><a class="nounderline abstract_t">Freund H, Hoover HC Jr, Atamian S, Fischer JE. Infusion of the branched chain amino acids in postoperative patients. Anticatabolic properties. Ann Surg 1979; 190:18.</a></li><li><a class="nounderline abstract_t">Pironi L, Arends J, Bozzetti F, et al. ESPEN guidelines on chronic intestinal failure in adults. Clin Nutr 2016; 35:247.</a></li><li><a class="nounderline abstract_t">McClave SA, Kozar R, Martindale RG, et al. Summary points and consensus recommendations from the North American Surgical Nutrition Summit. JPEN J Parenter Enteral Nutr 2013; 37:99S.</a></li><li><a class="nounderline abstract_t">Williams FN, Branski LK, Jeschke MG, Herndon DN. What, how, and how much should patients with burns be fed? Surg Clin North Am 2011; 91:609.</a></li><li><a class="nounderline abstract_t">Jeevanandam M, Young DH, Schiller WR. Nutritional impact on the energy cost of fat fuel mobilization in polytrauma victims. J Trauma 1990; 30:147.</a></li><li class="breakAll">https://www.east.org/education/practice-management-guidelines/nutritional-support--macronutrient-formulation-(assessment-of-energy-and-substrate-requirements) (Accessed on February 11, 2019).</li><li><a class="nounderline abstract_t">Frankenfield DC, Ashcraft CM. Description and prediction of resting metabolic rate after stroke and traumatic brain injury. Nutrition 2012; 28:906.</a></li><li><a class="nounderline abstract_t">Torgersen Z, Balters M. Perioperative nutrition. Surg Clin North Am 2015; 95:255.</a></li><li><a class="nounderline abstract_t">Jeon J, Kym D, Cho YS, et al. Reliability of resting energy expenditure in major burns: Comparison between measured and predictive equations. Clin Nutr 2019; 38:2763.</a></li><li><a class="nounderline abstract_t">Koretz RL. Death, morbidity and economics are the only end points for trials. Proc Nutr Soc 2005; 64:277.</a></li><li><a class="nounderline abstract_t">Seres DS. Surrogate nutrition markers, malnutrition, and adequacy of nutrition support. Nutr Clin Pract 2005; 20:308.</a></li><li><a class="nounderline abstract_t">Bharadwaj S, Ginoya S, Tandon P, et al. Malnutrition: laboratory markers vs nutritional assessment. Gastroenterol Rep (Oxf) 2016; 4:272.</a></li><li><a class="nounderline abstract_t">Boullata JI, Holcombe B, Sacks G, et al. Standardized Competencies for Parenteral Nutrition Order Review and Parenteral Nutrition Preparation, Including Compounding: The ASPEN Model. Nutr Clin Pract 2016; 31:548.</a></li><li><a class="nounderline abstract_t">Guenter P, Boullata JI, Ayers P, et al. Standardized Competencies for Parenteral Nutrition Prescribing: The American Society for Parenteral and Enteral Nutrition Model. Nutr Clin Pract 2015; 30:570.</a></li><li><a class="nounderline abstract_t">Boullata JI, Gilbert K, Sacks G, et al. A.S.P.E.N. clinical guidelines: parenteral nutrition ordering, order review, compounding, labeling, and dispensing. JPEN J Parenter Enteral Nutr 2014; 38:334.</a></li><li><a class="nounderline abstract_t">Mirtallo J, Canada T, Johnson D, et al. Safe practices for parenteral nutrition. JPEN J Parenter Enteral Nutr 2004; 28:S39.</a></li><li><a class="nounderline abstract_t">Ayers P, Adams S, Boullata J, et al. A.S.P.E.N. parenteral nutrition safety consensus recommendations. JPEN J Parenter Enteral Nutr 2014; 38:296.</a></li><li><a class="nounderline abstract_t">Mundi MS, Nystrom EM, Hurley DL, McMahon MM. Management of Parenteral Nutrition in Hospitalized Adult Patients [Formula: see text]. JPEN J Parenter Enteral Nutr 2017; 41:535.</a></li><li><a class="nounderline abstract_t">Nandivada P, Carlson SJ, Chang MI, et al. Treatment of parenteral nutrition-associated liver disease: the role of lipid emulsions. Adv Nutr 2013; 4:711.</a></li><li><a class="nounderline abstract_t">Leguina-Ruzzi AA, Ortiz R. Current Evidence for the Use of Smoflipid® Emulsion in Critical Care Patients for Parenteral Nutrition. Crit Care Res Pract 2018; 2018:6301293.</a></li><li><a class="nounderline abstract_t">Biesboer AN, Stoehr NA. A Product Review of Alternative Oil-Based Intravenous Fat Emulsions. Nutr Clin Pract 2016; 31:610.</a></li><li><a class="nounderline abstract_t">Martínez-Lozano Aranaga F, Gómez Ramos MJ, Sánchez Álvarez MDC. [Effectiveness and safety of two lipid emulsions for parenteral nutrition in postsurgical critically ill patients: Clinoleic® versus SMOFlipid®]. Nutr Hosp 2021; 38:5.</a></li><li><a class="nounderline abstract_t">Al-Leswas D, Eltweri AM, Chung WY, et al. Intravenous omega-3 fatty acids are associated with better clinical outcome and less inflammation in patients with predicted severe acute pancreatitis: A randomised double blind controlled trial. Clin Nutr 2020; 39:2711.</a></li><li><a class="nounderline abstract_t">Yarandi SS, Zhao VM, Hebbar G, Ziegler TR. Amino acid composition in parenteral nutrition: what is the evidence? Curr Opin Clin Nutr Metab Care 2011; 14:75.</a></li><li><a class="nounderline abstract_t">Sheean P, Gonzalez MC, Prado CM, et al. American Society for Parenteral and Enteral Nutrition Clinical Guidelines: The Validity of Body Composition Assessment in Clinical Populations. JPEN J Parenter Enteral Nutr 2020; 44:12.</a></li><li><a class="nounderline abstract_t">Edakkanambeth Varayil J, Yadav S, Miles JM, et al. Hyperglycemia During Home Parenteral Nutrition Administration in Patients Without Diabetes. JPEN J Parenter Enteral Nutr 2017; 41:672.</a></li><li><a class="nounderline abstract_t">Bolder U, Ebener C, Hauner H, et al. Carbohydrates - Guidelines on Parenteral Nutrition, Chapter 5. Ger Med Sci 2009; 7:Doc23.</a></li><li><a class="nounderline abstract_t">Rizzo JA, Rowan MP, Driscoll IR, et al. Vitamin C in Burn Resuscitation. Crit Care Clin 2016; 32:539.</a></li><li><a class="nounderline abstract_t">Chiang JM, Chang CJ, Jiang SF, et al. Pre-operative serum albumin level substantially predicts post-operative morbidity and mortality among patients with colorectal cancer who undergo elective colectomy. Eur J Cancer Care (Engl) 2017; 26.</a></li><li><a class="nounderline abstract_t">Maeda K, Nagahara H, Shibutani M, et al. A preoperative low nutritional prognostic index correlates with the incidence of incisional surgical site infections after bowel resection in patients with Crohn's disease. Surg Today 2015; 45:1366.</a></li><li><a class="nounderline abstract_t">Allard JP, Keller H, Teterina A, et al. Factors associated with nutritional decline in hospitalised medical and surgical patients admitted for 7 d or more: a prospective cohort study. Br J Nutr 2015; 114:1612.</a></li><li><a class="nounderline abstract_t">Cai J, Wu G, Qing A, et al. Organ Procurement and Transplantation Network/Scientific Registry of Transplant Recipients 2014 Data Report: Intestine. Clin Transpl 2014; :33.</a></li><li><a class="nounderline abstract_t">Llop J, Sabin P, Garau M, et al. The importance of clinical factors in parenteral nutrition-associated hypertriglyceridemia. Clin Nutr 2003; 22:577.</a></li><li><a class="nounderline abstract_t">Ocón Bretón MJ, Ilundain Gonzalez AI, Altemir Trallero J, et al. Predictive factors of hypertriglyceridemia in inhospital patients during total parenteral nutrition. Nutr Hosp 2017; 34:505.</a></li><li><a class="nounderline abstract_t">Sadu Singh BK, Narayanan SS, Khor BH, et al. Composition and Functionality of Lipid Emulsions in Parenteral Nutrition: Examining Evidence in Clinical Applications. Front Pharmacol 2020; 11:506.</a></li><li><a class="nounderline abstract_t">ApSimon M. Dispelling myths about intravenous fish oil-based lipid emulsions: a clinical perspective. Curr Opin Clin Nutr Metab Care 2018; 21:97.</a></li><li><a class="nounderline abstract_t">Tashiro T, Mashima Y, Yamamori H, Okui K. Alteration of lipoprotein profile during total parenteral nutrition with intralipid 10%. JPEN J Parenter Enteral Nutr 1986; 10:622.</a></li><li><a class="nounderline abstract_t">Solomon DM, Hollands JM, Pontiggia L, et al. Metabolic Complications Occur More Frequently in Older Patients Receiving Parenteral Nutrition. Nutr Clin Pract 2020; 35:627.</a></li><li><a class="nounderline abstract_t">Visschers RG, Olde Damink SW, Gehlen JM, et al. Treatment of hypertriglyceridemia in patients receiving parenteral nutrition. JPEN J Parenter Enteral Nutr 2011; 35:610.</a></li><li><a class="nounderline abstract_t">Mundi MS, Martindale RG, Hurt RT. Emergence of Mixed-Oil Fat Emulsions for Use in Parenteral Nutrition. JPEN J Parenter Enteral Nutr 2017; 41:3S.</a></li><li><a class="nounderline abstract_t">Badia-Tahull MB, Leiva-Badosa E, Llop-Talaverón J, et al. Liver function test alterations associated with parenteral nutrition in hospitalized adult patients: incidence and risk factors. Nutr Hosp 2012; 27:1279.</a></li><li><a class="nounderline abstract_t">Wu MH, Wang MY, Yang CY, et al. Randomized clinical trial of new intravenous lipid (SMOFlipid 20%) versus medium-chain triglycerides/long-chain triglycerides in adult patients undergoing gastrointestinal surgery. JPEN J Parenter Enteral Nutr 2014; 38:800.</a></li><li><a class="nounderline abstract_t">Tian H, Yao X, Zeng R, et al. Safety and efficacy of a new parenteral lipid emulsion (SMOF) for surgical patients: a systematic review and meta-analysis of randomized controlled trials. Nutr Rev 2013; 71:815.</a></li><li><a class="nounderline abstract_t">Bharadwaj S, Tandon P, Meka K, et al. Intestinal Failure: Adaptation, Rehabilitation, and Transplantation. J Clin Gastroenterol 2016; 50:366.</a></li><li><a class="nounderline abstract_t">Matarese LE. Nutrition and fluid optimization for patients with short bowel syndrome. JPEN J Parenter Enteral Nutr 2013; 37:161.</a></li></ol></div><div id="topicVersionRevision">Topic 104221 Version 14.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26427592" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Nutritional Status and Mortality in the Critically Ill.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25732218" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Comparative outcomes of total parenteral nutrition use in patients aged greater or less than 80 years of age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26300015" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Optimization of surgical outcomes with prehabilitation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30224150" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Effectiveness and cost-effectiveness of early nutritional support via the parenteral versus the enteral route for critically ill adult patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30156305" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Cost, Time, and Error Assessment During Preparation of Parenteral Nutrition: Multichamber Bags Versus Hospital-Compounded Bags.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27247538" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Enterocutaneous Fistula: Proven Strategies and Updates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22033622" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Metabolic and nutritional support of the enterocutaneous fistula patient: a three-phase approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28985843" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Total parenteral nutrition in patients following pancreaticoduodenectomy: lessons from 1184 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26472113" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Nutritional support in adults with chyle leaks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25023191" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Dysmotility disorders: a nutritional approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26245541" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Perioperative Parenteral Nutrition in Adults With Inflammatory Bowel Disease: A Review of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25311444" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : ESPEN endorsed recommendations. Definition and classification of intestinal failure in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28289510" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Critical analysis of feeding jejunostomy following resection of upper gastrointestinal malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34024556" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Associations between early parenteral nutrition and in-hospital outcomes in underweight patients with gastrointestinal surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34742137" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Early supplemental parenteral nutrition is associated with reduced mortality in critically ill surgical patients with high nutritional risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33389293" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Perioperative Management of Gastric Cancer Patients Treated With (Sub)Total Gastrectomy, Cytoreductive Surgery, and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Lessons Learned.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24495563" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : An intermittent exhaustion of the pool of glycogen in the human organism as a simple universal health promoting mechanism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23074240" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Adaptive reciprocity of lipid and glucose metabolism in human short-term starvation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26771786" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Use of total parenteral nutrition (TPN) in terminally ill gastrointestinal (GI) cancer patients (pts) compared to other malignancies (OM): A single-institution experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24810185" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Artificial nutrition at the end of life: ethical issues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16238518" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Terminal care: the last weeks of life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27542432" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The Role of Intravenous Fluids and Enteral or Parenteral Nutrition in Patients with Life-limiting Illness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16564074" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The effect of total parenteral nutrition on the survival of terminally ill ovarian cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34673022" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Risk Factors for Invasive Candida Infection in Critically Ill Patients: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2774262" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Intraoperative glucose infusion and blood lactate: endocrine and metabolic relationships during abdominal aortic surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24251716" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Refeeding syndrome: screening, incidence, and treatment during parenteral nutrition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21714640" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Early versus late parenteral nutrition in critically ill adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25946621" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Evolving paradigms in the nutritional support of critically ill surgical patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11606512" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : AGA technical review on parenteral nutrition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28385477" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : ESPEN guideline: Clinical nutrition in surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8439216" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : The effect of postoperative intravenous feeding (TPN) on outcome following major surgery evaluated in a randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7944656" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : A prospective randomized trial of total parenteral nutrition after major pancreatic resection for malignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/406484" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The effects of perioperative hyperalimentation on complications in patients with carcinoma and weight loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16837261" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Elective nutritional support after major surgery: a prospective randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/698542" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Liver function and lactate metabolism in the ill surgical patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23689848" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Early parenteral nutrition in critically ill patients with short-term relative contraindications to early enteral nutrition: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11308231" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Total parenteral nutrition in the surgical patient: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/812456" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Malnutrition in cardiac surgical patients. Results of a prospective, randomized evaluation of early postoperative parenteral nutrition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2119446" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Nutritional support after liver transplantation: a randomized prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3142196" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Postoperative hypocaloric parenteral nutrition. A study in patients without neoplasm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9654632" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Nutritional depletion in staged spinal reconstructive surgery. The effect of total parenteral nutrition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8505831" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : The importance of a source of sufficient protein in postoperative hypocaloric partial parenteral nutrition support.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6402051" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The effect of isotonic amino acid infusions on serum proteins and muscle breakdown following surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6541715" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : An evaluation of peripheral essential amino acid infusion following major surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8633913" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Protein-sparing therapy after major abdominal surgery: lack of clinical effects. Protein-Sparing Therapy Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16843906" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Study of hypocaloric peripheral parenteral nutrition in postoperative patients (European project).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3082301" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Effect of immediate postoperative nutritional support on length of hospitalization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6405838" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Effect of postoperative total parenteral nutrition (TPN) as an adjunct to gastrectomy for advanced gastric carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2127338" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : The value of short-term peripheral parenteral nutrition after colorectal surgery: a comparative study with conventional postoperative intravenous fluid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/464673" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Infusion of the branched chain amino acids in postoperative patients. Anticatabolic properties.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26944585" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : ESPEN guidelines on chronic intestinal failure in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24009254" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Summary points and consensus recommendations from the North American Surgical Nutrition Summit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21621699" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : What, how, and how much should patients with burns be fed?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2106037" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Nutritional impact on the energy cost of fat fuel mobilization in polytrauma victims.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2106037" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Nutritional impact on the energy cost of fat fuel mobilization in polytrauma victims.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22464552" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Description and prediction of resting metabolic rate after stroke and traumatic brain injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25814105" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Perioperative nutrition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30579670" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Reliability of resting energy expenditure in major burns: Comparison between measured and predictive equations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16048658" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Death, morbidity and economics are the only end points for trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16207668" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Surrogate nutrition markers, malnutrition, and adequacy of nutrition support.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27174435" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Malnutrition: laboratory markers vs nutritional assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27317615" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Standardized Competencies for Parenteral Nutrition Order Review and Parenteral Nutrition Preparation, Including Compounding: The ASPEN Model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26078288" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Standardized Competencies for Parenteral Nutrition Prescribing: The American Society for Parenteral and Enteral Nutrition Model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24531708" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : A.S.P.E.N. clinical guidelines: parenteral nutrition ordering, order review, compounding, labeling, and dispensing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15568296" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Safe practices for parenteral nutrition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24280129" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : A.S.P.E.N. parenteral nutrition safety consensus recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27587535" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Management of Parenteral Nutrition in Hospitalized Adult Patients [Formula: see text].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24228202" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Treatment of parenteral nutrition-associated liver disease: the role of lipid emulsions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30584476" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Current Evidence for the Use of Smoflipid®Emulsion in Critical Care Patients for Parenteral Nutrition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27528126" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : A Product Review of Alternative Oil-Based Intravenous Fat Emulsions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33319565" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : [Effectiveness and safety of two lipid emulsions for parenteral nutrition in postsurgical critically ill patients: Clinoleic®versus SMOFlipid®].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32921364" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Intravenous omega-3 fatty acids are associated with better clinical outcome and less inflammation in patients with predicted severe acute pancreatitis: A randomised double blind controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21076291" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Amino acid composition in parenteral nutrition: what is the evidence?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31216070" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : American Society for Parenteral and Enteral Nutrition Clinical Guidelines: The Validity of Body Composition Assessment in Clinical Populations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26392165" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Hyperglycemia During Home Parenteral Nutrition Administration in Patients Without Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20049080" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Carbohydrates - Guidelines on Parenteral Nutrition, Chapter 5.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27600125" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Vitamin C in Burn Resuscitation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26526411" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Pre-operative serum albumin level substantially predicts post-operative morbidity and mortality among patients with colorectal cancer who undergo elective colectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25319215" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : A preoperative low nutritional prognostic index correlates with the incidence of incisional surgical site infections after bowel resection in patients with Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26369948" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Factors associated with nutritional decline in hospitalised medical and surgical patients admitted for 7 d or more: a prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26281125" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Organ Procurement and Transplantation Network/Scientific Registry of Transplant Recipients 2014 Data Report: Intestine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14613761" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : The importance of clinical factors in parenteral nutrition-associated hypertriglyceridemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28627182" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Predictive factors of hypertriglyceridemia in inhospital patients during total parenteral nutrition</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32410990" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Composition and Functionality of Lipid Emulsions in Parenteral Nutrition: Examining Evidence in Clinical Applications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29256925" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Dispelling myths about intravenous fish oil-based lipid emulsions: a clinical perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3099006" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Alteration of lipoprotein profile during total parenteral nutrition with intralipid 10%.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32579257" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Metabolic Complications Occur More Frequently in Older Patients Receiving Parenteral Nutrition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21799190" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Treatment of hypertriglyceridemia in patients receiving parenteral nutrition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29161196" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Emergence of Mixed-Oil Fat Emulsions for Use in Parenteral Nutrition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23165574" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Liver function test alterations associated with parenteral nutrition in hospitalized adult patients: incidence and risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24285251" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Randomized clinical trial of new intravenous lipid (SMOFlipid 20%) versus medium-chain triglycerides/long-chain triglycerides in adult patients undergoing gastrointestinal surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24180519" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Safety and efficacy of a new parenteral lipid emulsion (SMOF) for surgical patients: a systematic review and meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26974760" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Intestinal Failure: Adaptation, Rehabilitation, and Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23264168" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Nutrition and fluid optimization for patients with short bowel syndrome.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
